Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 17/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 12/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328879 | 0.93 | ADRB3 (0.82) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6335553 | 0.92 | ADRB3 (0.87) | ADRB3ADRB1ADRB2CYP3A4CYP2D6 | |
| SCHEMBL6338059 | 0.91 | ADRB3 (0.83) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6333736 | 0.90 | ADRB3 (0.83) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6331118 | 0.88 | ADRB3 (0.56) | ADRB3ADRB1ADRB2CYP3A4CYP2D6 | |
| SCHEMBL6326372 | 0.85 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6788352 | 0.84 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6326352 | 0.84 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6328869 | 0.84 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6330274 | 0.83 | ADRB3 (0.81) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.